Cannara Announces Strategic C$6.3 Million Non-Brokered Private Placement Priced at C$2.10 per Common Share February 4, 2026
Cannara Achieves OTCQX Qualification and Announces Release of Fiscal Q1 2026 Financial Results on January 26, 2026 January 14, 2026
Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch January 2, 2026
Cannara Biotech Delivers Record Fiscal 2025 Revenue and Profitability, Achieves First Year of Positive Retained Earnings November 24, 2025
Cannara Biotech Inc. to Announce Fiscal Q4 2025 and Fiscal Year 2025 Financial Results on November 24, 2025 and Provides Board Update November 17, 2025
Cannara Announces DTC Eligibility to Facilitate U.S. Investor Access and Strengthens Balance Sheet through completion of Debt-to-Equity Conversion October 7, 2025
Cannara Announces Amendment and Upsize of BMO Credit Facility to Support Facility Expansion at Valleyfield August 21, 2025
Cannara Biotech Delivers Highest Revenue and Profitability Since Inception in Fiscal Q3 2025 July 28, 2025
Cannara Secures 5 Key Listings in Québec’s New Vape Cartridge Category Including to be Released Live Rosin Vapes July 24, 2025
Cannara Reduces Cost of Debt with Lower Interest Rate and Partial Debenture Repayment; Wins 2025 Brand of the Year June 18, 2025
